SCHEMBL9101820

SCHEMBL9101820

CC(C)[C@@H](CN1CC(F)C1)N(C)C(=O)c1ccc(F)c(C(F)(F)F)c1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HDAC8 Q9BY41 1/20 0.45
▸ TAS1R3 Q7RTX0 2/20 0.39
▸ TAS1R1 Q7RTX1 2/20 0.39
▸ TAS1R2 Q8TE23 2/20 0.39
▸ GPBAR1 Q8TDU6 1/20 0.37
▸ UBE2M P61081 2/20 0.36
▸ DCUN1D1 Q96GG9 2/20 0.36
▸ SLC6A9 P48067 2/20 0.36
▸ KCNH2 Q12809 2/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ GRIN2B Q13224 3/20 0.35
▸ GRIN1 Q05586 1/20 0.35
▸ NOTUM Q6P988 1/20 0.34
▸ P2RX7 Q99572 1/20 0.34
▸ VNN1 O95497 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9101826 1.00 HDAC8 (0.45) HDAC8TAS1R3TAS1R1TAS1R2GPBAR1
SCHEMBL9277511 0.88 HDAC8 (0.45) HDAC8TAS1R3TAS1R1TAS1R2GPBAR1
SCHEMBL9104310 0.87 HDAC8 (0.47) HDAC8TAS1R3TAS1R1TAS1R2GPBAR1
SCHEMBL9104321 0.87 HDAC8 (0.47) HDAC8TAS1R3TAS1R1TAS1R2GPBAR1
SCHEMBL9104502 0.86 HRH3 (0.44) HDAC8TAS1R3TAS1R1TAS1R2CYP2D6
SCHEMBL9104486 0.86 HRH3 (0.44) HDAC8TAS1R3TAS1R1TAS1R2CYP2D6
SCHEMBL9105573 0.86 MAOA (0.36) KCNH2GRIN2BGRIN1
SCHEMBL9105581 0.86 MAOA (0.36) KCNH2GRIN2BGRIN1
SCHEMBL9101316 0.85 MAOA (0.38) TAS1R3TAS1R1TAS1R2GPBAR1CYP2D6
SCHEMBL9101325 0.85 MAOA (0.38) TAS1R3TAS1R1TAS1R2GPBAR1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025082731-A1 INTRANASAL FORMULATIONS FOR TREATING OBSTRUCTIVE SLEEP APNEA MOSANNA THERAPEUTICS AG (CH) 2025-04-24 — — WO disclosed
US-20130143858-A1 COMPOUNDS AND THEIR USE AS IKACH BLOCKERS ASTRAZENECA AB (SE) 2013-06-06 — — US disclosed
US-8361998-B2 Compounds and their use as IKACh blockers ASTRAZENECA AB 2013-01-29 — — US disclosed
US-20120142659-A1 COMPOUNDS AND THEIR USE AS IKACH BLOCKERS ASTRAZENECA AB (SE) 2012-06-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130143858-A1 COMPOUNDS AND THEIR USE AS IKACH BLOCKERS KCNH2, KCNJ2, KCNH3 HDAC8 1995/4885TAS1R3 3687/4885TAS1R1 3249/4885
US-20120142659-A1 COMPOUNDS AND THEIR USE AS IKACH BLOCKERS KCNH2, KCNJ2, KCNH3 HDAC8 1995/4885TAS1R3 3687/4885TAS1R1 3249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback